Physician profile
Thomas Ryan Temple
NPI 1093231631
$3,789.41
in general payments reported to CMS, 2019-2025
24 companies · $754 in 2025
The $754 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $811 · 2023: $355 · 2024: $1,124 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,472 · Travel and Lodging: $761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.14 |
| Travel and Lodging | $761.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $810.29 | 2024-2025 | Mako |
| Abbott Laboratories | $682.95 | 2021-2023 | Octrode |
| Abbvie INC. | $418.82 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $275.84 | 2024-2025 | Airsupra, Farxiga |
| Genzyme Corporation | $223.36 | 2025 | |
| Lilly USA, LLC | $195.13 | 2024-2025 | Zepbound, Mounjaro |
| Biodelivery Sciences International, INC. | $151.13 | 2021 | |
| Vertos Medical, INC. | $134.76 | 2021-2022 | |
| Novo Nordisk INC | $123.76 | 2023 | Wegovy |
| Glaxosmithkline, LLC. | $105.60 | 2024 | Arexvy |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Dexcom, INC. | $80.39 | 2022 | |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.82 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.29 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $59.14 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $53.60 | 2022 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Exact Sciences Corporation | $37.77 | 2023 | Cologuard Collection Kit |
| Bioventus LLC | $20.88 | 2022 | |
| Baudax Bio INC. | $18.69 | 2021 | |
| Stimwave Technologies Incorporated | $15.01 | 2022 | |
| Pfizer INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.